Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

HISTORICAL FACTS: Mersana therapeutics s return on capital employed overview | History Defined

According to Benzinga Pro data, during Q1, Mersana Therapeutics (NASDAQ:MRSN) posted sales of $2.04 million. Earnings were up 3.52%, but Mersana Therapeutics still reported an overall loss of $47.26 million. In Q4, Mersana Therapeutics brought in $11.00 thousand in sales but lost $48.98 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.